PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 11, Issue 2, 2012, Pages 143-150

  Sood, Arjun ^a,b   McClain, Danielle ^a,b   Maitra, Radhashree ^a,b   Basu Mallick, Atrayee ^a,b   Seetharam, Raviraja ^a,b   Kaubisch, Andreas ^a,b   Rajdev, Lakshmi ^a,b   Mariadason, John M ^b   Tanaka, Kathryn ^a,b   Goel, Sanjay ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

Anti EGFR; Biomarker; Colorectal cancer; KRAS; PIK3CA mutations; PTEN

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; K RAS PROTEIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR MARKER;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME SUBUNIT; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHYLATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; TREATMENT DURATION;

EID: 84860702958     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.12.001     Document Type: Article

References (57)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. R.M. Goldberg, M.L. Rothenberg, E. Van Cutsem The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 2007 38 50 (Pubitemid 46143501)
3. A. Grothey, M.M. Sugrue, D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
4. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048 (Pubitemid 350106711)
5. C. Tournigand, T. Andre, E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
6. D. Cunningham, Y. Humblet, S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
7. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208 (Pubitemid 41079832)
8. R.N. Jorissen, F. Walker, N. Pouliot Epidermal growth factor receptor: mechanisms of activation and signalling Exp Cell Res 284 2003 31 53 (Pubitemid 36331965)
9. K.M. Quesnelle, A.L. Boehm, J.R. Grandis STAT-mediated EGFR signaling in cancer J Cell Biochem 102 2007 311 319 (Pubitemid 47519405)
10. A. Lievre, J.B. Bachet, D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
11. W. De Roock, H. Piessevaux, J. De Schutter KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 2008 508 515 (Pubitemid 351325672)
12. F. Di Fiore, F. Blanchard, F. Charbonnier Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy Br J Cancer 96 2007 1166 1169 (Pubitemid 46625066)
13. A. Lievre, P. Laurent-Puig Genetics: predictive value of KRAS mutations in chemoresistant CRC Nat Rev Clin Oncol 6 2009 306 307
14. F. Loupakis, A. Ruzzo, C. Cremolini KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 2009 715 721
15. F. Di Nicolantonio, M. Martini, F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
16. J. Tol, I.D. Nagtegaal, C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
17. S.D. Richman, M.T. Seymour, P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
18. E. Van Cutsem, I. Lang, G. Folprecht Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome J Clin Oncol 28 suppl 2010 abstr 3570
19. R.G. Amado, M. Wolf, M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
20. D.J. Freeman, T. Juan, M. Reiner Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 2008 184 190 (Pubitemid 351758148)
21. S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2007 2643 2648 (Pubitemid 46548951)
22. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
23. A. Lievre, J.B. Bachet, V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 2008 374 379 (Pubitemid 351171687)
24. M. Jhawer, S. Goel, A.J. Wilson PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 2008 1953 1961 (Pubitemid 351416582)
25. H. Prenen, J. De Schutter, B. Jacobs PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer Clin Cancer Res 15 2009 3184 3188
26. F. Perrone, A. Lampis, M. Orsenigo PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann Oncol 20 2009 84 90
27. F. Loupakis, L. Pollina, I. Stasi PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2009 2622 2629
28. M. Frattini, P. Saletti, E. Romagnani PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 97 2007 1139 1145 (Pubitemid 47587019)
29. A. Sartore-Bianchi, M. Martini, F. Molinari PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies Cancer Res 69 2009 1851 1857
30. W. De Roock, B. Claes, D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
31. A.J. Philp, I.G. Campbell, C. Leet The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors Cancer Res 61 2001 7426 7429 (Pubitemid 32995029)
32. G. Guanti, N. Resta, C. Simone Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis Hum Mol Genet 9 2000 283 287 (Pubitemid 30052752)
33. A. Goel, C.N. Arnold, D. Niedzwiecki Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 2004 3014 3021 (Pubitemid 38581399)
34. M. Ronaghi, E. Elahi Discovery of single nucleotide polymorphisms and mutations by pyrosequencing Comp Funct Genomics 3 2002 51 56 (Pubitemid 34187811)
35. D. Packham, R.L. Ward, V. Ap Lin Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers Diagn Mol Pathol 18 2009 62 71
36. S. Ogino, T. Kawasaki, M. Brahmandam Sensitive sequencing method for KRAS mutation detection by pyrosequencing J Mol Diagn 7 2005 413 421 (Pubitemid 41149657)
37. Y.H. Tan, Y. Liu, K.W. Eu Detection of BRAF V600E mutation by pyrosequencing Pathology 40 2008 295 298 (Pubitemid 351563933)
38. C. Spittle, M.R. Ward, K.L. Nathanson Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma J Mol Diagn 9 2007 464 471 (Pubitemid 47434113)
39. Y. Zhu, A. Wloch, Q. Wu Involvement of PTEN promoter methylation in cerebral cavernous malformations Stroke 40 2009 820 826
40. J.K. Wiencke, S. Zheng, N. Jelluma Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro Oncol 9 2007 271 279 (Pubitemid 47169659)
41. S. Khan, T. Kumagai, J. Vora PTEN promoter is methylated in a proportion of invasive breast cancers Int J Cancer 112 2004 407 410 (Pubitemid 39390604)
42. J.G. Herman, J.R. Graff, S. Myohanen Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci U S A 93 1996 9821 9826 (Pubitemid 26296693)
43. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
44. I.U. Ali, L.M. Schriml, M. Dean Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity J Natl Cancer Inst 91 1999 1922 1932
45. D. Bonneau, M. Longy Mutations of the human PTEN gene Hum Mutat 16 2000 109 122 (Pubitemid 30604900)
46. M. Frattini, S. Signoroni, S. Pilotti Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer Cancer Res 65 2005 11227 (Pubitemid 41713394)
47. The label change by the USFDA on the use of the KRAS biomarker for the drugs cetuximab and panitumumab http://www.fda.gov/AboutFDA/CentersOffices/CDER/ ucm172905.htm 2009 Accessed: August 4, 2011
48. S. Tejpar, M. Bertagnolli, F. Bosman Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery Oncologist 15 2010 390 404
49. C.J. Allegra, J.M. Jessup, M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
50. C. Bokemeyer, I. Bondarenko, J.T. Hartmann KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience J Clin Oncol 26 suppl 2008 abstr 4000
51. C.J. Punt, J. Tol, C.J. Rodenburg A randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) J Clin Oncol 26 suppl 2008 abstr LBA4011
52. W. De Roock, D.J. Jonker, F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
53. C. Mao, R.Y. Liao, Q. Chen Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer Br J Cancer 102 2010 940
54. F. Molinari, V. Martin, P. Saletti Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant Br J Cancer 100 2009 1087 1094
55. P. Laurent-Puig, A. Cayre, G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 2009 5924 5930
56. I. Simon, S. Tian, V. Moreno The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer J Clin Oncol 29 suppl 2011 abstr 3534
57. K.L. Bennett, J. Mester, C. Eng Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome JAMA 304 2010 2724 2731